Biolegend, 115543, Brilliant Violet 785™ anti-mouse CD19 Antibody, 125microl

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse CD19-expressing K562 human erythroleukemia cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence7.
Application References(PubMed link indicates BioLegend citation): Shoham T, et al. 2003. J. Immunol. 171:4062. (FC) Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. (FC) Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC) Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed Olive V, et al. 2013. Elife. 2:822. PubMed Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations: Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed Melo-Silva CR, et al. 2022. Cell Rep. 41:111676. PubMed Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed Gao Y, et al. 2023. iScience. 26:106729. PubMed Zengel J, et al. 2023. Nat Methods. . PubMed Hu Q, et al. 2022. Cell Rep. 40:111035. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Ersching J et al. 2017. Immunity. 46(6):1045-1058 . PubMed Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed Xu AQ, et al. 2020. Elife. 9:00. PubMed Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed Devos M, et al. 2020. J Exp Med. 217:00:00. PubMed Szafran BN, et al. 2021. Chemical Research in Toxicology. 34(6):1556-1571. PubMed Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed Lissner MM, et al. 2020. Elife. 9:00. PubMed Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed Kurniawan H, et al. 2020. Cell Metabolism. 31(5):920-936. PubMed Jacque E, et al. 2015. J Exp Med. 212:883. PubMed Alameh MG, et al. 2021. Immunity. 54:2877. PubMed Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed Souza SP, et al. 2021. PLoS Pathog. 17:e1010081. PubMed Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed Graf R et al. 2019. Cell reports. 26(5):1098-1103 . PubMed Lu X, et al. 2019. Circ Res. 125:1055. PubMed Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed Wilmore JR, et al. 2022. Front Immunol. 12:791095. PubMed Mirsoian A, et al. 2014. J Exp Med. 211:2373. PubMed Castro‐Dopico T et al. 2019. Immunity. 50(4):1099-1114 . PubMed Jones D, et al. 2015. J Immunol. 195: 4753 - 4759. PubMed Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
RRID: AB_11218994 (BioLegend Cat. No. 115543)
Structure: Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution: Pro-B cells to mature B cells (during development), follicular dendritic cells
Function: Modulates B cell activation and differentiation
Ligand/Receptor: CD21, CD81, Leu-13
Cell Type: B cells, Dendritic cells
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341. 2. Krop I, et al. 1996. Eur. J. Immunol. 26:238. 3. Krop I, et al. 1996. J. Immunol. 157:48. 4. Tedder TF, et al. 1994. Immunol. Today 15:437.
Gene ID: 12478
UniProt: View information about CD19 on UniProt.org
Clone: 6D5
Regulatory Status: RUO
Other Names: B4
Isotype: Rat IgG2a, κ